Structural and immunogenetic signatures guide CD4-mimetic HIV vaccine development

Daniel L V Bader1, Claudia T Flynn2, Oleksandr Kalyuzhniy3

  • 1Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Cell Reports
|April 17, 2026
PubMed
Summary

Developing an HIV vaccine requires understanding broadly neutralizing antibodies (bnAbs). This study analyzes VH1-46 bnAbs, revealing diverse structures and identifying classes that can guide future vaccine design for optimal targeting.